Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus MIDAZOLAM IN 0 8 SODIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus MIDAZOLAM IN 0 8 SODIUM CHLORIDE.
MAGNESIUM SULFATE vs MIDAZOLAM IN 0.8% SODIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Midazolam is a benzodiazepine that potentiates gamma-aminobutyric acid (GABA) type A receptor activity, resulting in increased chloride ion influx, neuronal hyperpolarization, and central nervous system depression.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
IV: 0.5-2 mg every 2-5 minutes as needed for procedural sedation. IM: 2-5 mg 30-60 minutes before procedure.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Terminal elimination half-life: 1.8-6.4 hours (mean 3.1 h) in healthy adults; prolonged in elderly (5-6 h), obesity, hepatic impairment (up to 13 h), and critical illness (up to 20+ h).
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Renal (approx. 45-57% as glucuronide conjugates; <1% unchanged); biliary/fecal (approx. 2-10%)
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."